Annals of Hematology

, Volume 88, Issue 7, pp 647–652

L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type

  • Weiben Yong
  • Wen Zheng
  • Jun Zhu
  • Yuntao Zhang
  • Xiaopei Wang
  • Yan Xie
  • Ningjing Lin
  • Bo Xu
  • Aiping Lu
  • Jiyou Li
Original Article

DOI: 10.1007/s00277-008-0669-3

Cite this article as:
Yong, W., Zheng, W., Zhu, J. et al. Ann Hematol (2009) 88: 647. doi:10.1007/s00277-008-0669-3

Abstract

There is no standard salvage regimen for patients with refractory and relapsed extranodal NK/T-cell lymphoma (NKTCL), nasal type. This study was conduced to evaluate the efficacy of L-asparaginase-based regimen as a salvage regimen, on refractory and relapsed extranodal NKTCL, nasal type. Between March 1996 and March 2008, 45 patients with refractory and relapsed extranodal NKTCL, nasal type, were studied retrospectively. All patients were treated with L-asparaginase-based salvage regimen. Thirty-nine patients also received primary involved-field radiation after L-asparaginase-based chemotherapy. The complete response rate, partial response rate, and overall response rate for the whole group were 55.6%, 26.7%, and 82.2%, respectively. Both of 3-year and 5-year overall survival (OS) rates were 66.9%. The major adverse effects of L-asparaginase were myelosuppression, liver dysfunction, hyperglycemia, and allergic reaction. In general, the side effects could be tolerated. On univariate analysis, age, the stage of disease, and performance status were found to be prognostic factors influencing OS. On multivariate analysis, the stage of disease and age were independent prognostic factors for OS. L-Asparaginase-based regimen was obviously effective for the patients with refractory and relapsed extranodal NKTCL, nasal type.

Keywords

Extranodal NK/T-cell lymphoma L-Asparaginase Radiotherapy Chemotherapy Prognostic factor 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Weiben Yong
    • 1
  • Wen Zheng
    • 1
  • Jun Zhu
    • 1
  • Yuntao Zhang
    • 1
  • Xiaopei Wang
    • 1
  • Yan Xie
    • 1
  • Ningjing Lin
    • 1
  • Bo Xu
    • 2
  • Aiping Lu
    • 3
  • Jiyou Li
    • 3
  1. 1.Department of Medical Oncology, Beijing Cancer Hospital & Institute, the School of OncologyPeking UniversityBeijingPeople’s Republic of China
  2. 2.Department of Radiation Oncology, Beijing Cancer Hospital & Institute, the School of OncologyPeking UniversityBeijingPeople’s Republic of China
  3. 3.Department of Pathology, Beijing Cancer Hospital & Institute, the School of OncologyPeking UniversityBeijingPeople’s Republic of China

Personalised recommendations